Images List Premium Download Classic

Breast Cancer

Breast Cancer-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
NEW Methods of treating cancer
June 21, 2018 - N°20180171288

Compositions and methods of treating a subject with cancer are described. The methods include administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a compound with the dual characteristics or restoring function of the c-cbl ubiquitin ligase in cancer cells and in also worsening sublethal lysosomal dysfunction, preferably in combination with an agent capable of making ...
NEW Piperidine derivative and preparation method and pharmaceutical use thereof
June 21, 2018 - N°20180170943

The present invention relates to a piperidine derivative and the preparation method and a pharmaceutical use thereof. In particular, the present invention relates to the piperidine derivative as shown by general formula (i) and the preparation method thereof and a pharmaceutical composition containing the same, and the use thereof as an estrogen receptor modulator in the treatment of estrogen receptor ...
NEW Agtr1 aptamer-anticancer drug complex for cancer cell chemotherapy
June 21, 2018 - N°20180169251

This invention relates to a complex for cancer cell chemotherapy and, more particularly, to an agtr1 aptamer-anticancer drug complex for chemotherapy of cancer cells, which includes a nucleic acid aptamer specifically binding to agtr1 and an anticancer drug linked with the nucleic acid aptamer, so that agtr1-positive (overexpressed) breast cancer cells are selectively targeted and killed.. .
Breast Cancer Patent Pack
Download 198+ patent application PDFs
Breast Cancer Patent Applications
Download 198+ Breast Cancer-related PDFs
For professional research & prior art discovery
inventor
  • 198+ full patent PDF documents of Breast Cancer-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Antitumor agent
Public University Corporation Nagoya City University
June 14, 2018 - N°20180163208

This invention provides a composition and a method for treating or preventing a subject having a tumor that more highly expresses a tug1 gene than in normal tissues (e.g., brain tumor, breast cancer, colon cancer, prostate cancer, liver cancer, lung cancer, leukemia, or lymphoma), which composition comprises, as an active ingredient, a nucleic acid that inhibits the high expression ...
Antibodies specific for claudin 6 (cldn6)
Johannes Gutenberg-universitat Mainz
June 14, 2018 - N°20180162938

The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing claudin-6 (cldn6), including tumor-related diseases such as ovarian cancer, lung cancer, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, malignant melanoma, head and neck cancer, sarcoma, bile duct cancer, cancer of the urinary bladder, kidney cancer, colon cancer, placental choriocarcinoma, ...
B1sp fusion protein therapeutics, methods, and uses
The University Of British Columbia
June 14, 2018 - N°20180162923

Provided are methods, uses and pharmaceutical compositions for treatment of cancer with a b1sp fusion protein in a biologically effective amount sufficient to cause cell death of a prostate cancer cell or to inhibit proliferation of the prostate cancer cells. The cancer may be prostate cancer, breast cancer, ovarian cancer, bladder cancer, kidney cancer, glioblastoma or endometrial cancer.
Breast Cancer Patent Pack
Download 198+ patent application PDFs
Breast Cancer Patent Applications
Download 198+ Breast Cancer-related PDFs
For professional research & prior art discovery
inventor
  • 198+ full patent PDF documents of Breast Cancer-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Compounds for the modulation of myc activity
Syros Pharmaceuticals, Inc.
June 14, 2018 - N°20180162851

The present invention provides novel compounds of formula (i) and formula (ii) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases, e.g., cancers (e.g., breast cancer, prostate cancer, lymphoma, lung cancer, pancreatic cancer, ovarian cancer, neuroblastoma, ...
211-astatine containing radiotherapeutics for the treatment of cancer
The Trustees Of The University Of Pennsylvania
June 14, 2018 - N°20180162818

Described herein is an alpha-emitting radionuclide, 211at, which has been incorporated into a selective sigma-2 ligand moiety to provide cytotoxic capabilities to a chemical compound. As described herein, a compound of formula (i), wherein r1-r4, m, and n are defined herein, was prepared and utilized in in vitro and in vivo tumor targeting of alpha-emitting sigma-2 ligand in a ...
Methods for diagnosis and prognosis of cancers of epithelial origin
Children's Medical Center Corporation
June 07, 2018 - N°20180156808

Adam 12 expression and activity are up regulated in patients that have cancers of epithelial origin, such as breast cancer, colon cancer, prostate cancer, liver cancer, bladder cancer, pancreatic cancer, ovarian cancer, cervical cancer, lung cancer, and skin cancer, as well as others: accordingly, the present invention is directed to methods for prognostic evaluation, and diagnosis of cancers of epithelial origin. ...
Use of an mirna to reduce proliferation of a cancer cell
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College
June 07, 2018 - N°20180155726

A method is provided for decreasing at least one of the proliferation and the migration of a cancer cell comprising contacting a cancer cell with an effective amount of a pharmaceutically acceptable composition comprising a microrna (mirna) having a nucleotide sequence having at least 80% sequence similarity to the nucleotide sequence of mir-3189-3p derived from the mir-3189 mitron of ...
Blocking il-9 signaling in conjunction with chemotherapy to treat cancer
Mayo Foundation For Medical Education And Research
June 07, 2018 - N°20180153994

This document provides methods and materials related to using inhibitors of il-9 signaling in conjunction with chemotherapy to treat cancer (e.g., solid tumors). For example, methods and materials for using inhibitors of il-9 signaling (e.g., anti-il9 antibody preparations) in conjunction with chemotherapy to treat cancer (e.g., solid tumors such as breast cancer tumors or colon cancer tumors) ...
Fused bicyclic pyrimidine derivatives and uses thereof
Dana-farber Cancer Institute, Inc.
June 07, 2018 - N°20180153894

The present invention provides novel compounds of formula (i), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., lung cancer, breast cancer, leukemia, lymphoma, melanoma, multiple myeloma, ewing's sarcoma, ...
Treatment of breast cancer by concomitant administration of a bromodomain inhibitor and a second agent
Gilead Sciences, Inc.
June 07, 2018 - N°20180153868

Methods for treating breast cancer comprising administering to a subject in need thereof a bromodomain inhibitor concomitantly with a second agent. The second agent may be an aromatase inhibitor, a selective estrogen receptor modulator, or a selective estrogen receptor down-regulator.
Breast Cancer Patent Pack
Download 198+ patent application PDFs
Breast Cancer Patent Applications
Download 198+ Breast Cancer-related PDFs
For professional research & prior art discovery
inventor
  • 198+ full patent PDF documents of Breast Cancer-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Combination liposomal pharmaceutical formulations
Cureport, Inc.
June 07, 2018 - N°20180153806

Docetaxel and doxorubicin can be formulated in liposomal pharmaceutical compositions. In various embodiments, the pharmaceutical compositions include (i) a first liposome type comprising a first lipid layer comprising an unsaturated phospholipid, cholesterol or a cholesterol derivative, dc-cholesterol, a cationic lipid, and preferably a pegylated phospholipid, and a first active pharmaceutical ingredient (api) comprising docetaxel in the first lipid layer; and (...
Compositions and methods for diagnosing breast cancer
Trustees Of Tufts College
May 31, 2018 - N°20180149653

The invention provides methods and compositions for distinguishing breast cancer.. .
T cell receptor-like antibodies specific for a prame peptide
Eureka Therapeutics, Inc.
May 31, 2018 - N°20180148503

The presently disclosed subject matter provides antigen-binding proteins that specifically bind to preferentially expressed antigen of melanoma (prame), including humanized, chimeric and fully human antibodies against prame, antibody fragments (e.g., scfv, fab and f(ab)2), chimeric antigen receptors (cars), fusion proteins, and conjugates thereof. The antigen-binding proteins and antibodies bind to a prame peptide/hla class i molecule complex.
Novel compounds as rearranged during transfection (ret) inhibitors
Glaxosmithkline Intellectual Property Development Limited
May 31, 2018 - N°20180147194

This invention relates to novel compounds which are inhibitors of the rearranged during transfection (ret) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to ...
Breast cancer therapeutic agent containing 5'-hydroxy-5-nitro-indirubin-3'-oxime as active ingredient
Anygen Co., Ltd.
May 31, 2018 - N°20180147182

A breast cancer therapeutic agent containing 5′-hydroxy-5-nitro-indirubin-3′-oxime as active ingredient has been disclosed. Further, a breast cancer therapeutic agent containing 5′-hydroxy-5-nitro-indirubin-3′-oxime as cyclin-dependent kinase (cdk) inhibitor, wherein said breast cancer is triple negative breast cancer (tnbc) and/or an estrogen receptor (er) positive breast cancer including the tamoxifen-resistant estrogen receptor (er) positive ...
Mmtv-sv40-spy1a and spy1a-ptre transgenic mouse models
May 31, 2018 - N°20180146650

In one aspect, the invention provides a transgenic non-human animal model having germ cells and somatic cells containing an endogenous mmtv-sv40-spy1a gene sequence introduced into said animal model or an ancestor of said animal model at an embryonic stage, wherein said gene sequence comprises a mouse mammary tumor virus gene (mmtv), a functionally disrupted sv40 gene (sv40) and ...
Methods for diagnosis, prognosis and treatment of primary and metastatic basal-like breast cancer and other ...
May 24, 2018 - N°20180142305

In one embodiment, methods of theranostic classification of a breast cancer tumor are provided, wherein the classification is determined by detecting an expression level of foxc1. In other embodiments, methods for predicting a prognosis of a basal-like breast cancer and methods of treating a basal-like breast cancer are provided.
Compositions and methods for screening solid tumors
Quest Diagnostics Investments Incorporated
May 24, 2018 - N°20180142304

The present technology relates to methods for determining whether a patient diagnosed with breast cancer, colorectal cancer, melanoma or lung cancer will benefit from or is predicted to be responsive to treatment with an individual therapeutic agent or a specific combination of therapeutic agents. These methods are based on screening a patient's solid tumors and detecting alterations in target nucleic ...
Loading